lirafugratinib   Click here for help

GtoPdb Ligand ID: 12370

Synonyms: example 343 [WO2020231990A1] | Lyrfigtu® | RLY-4008 | RLY4008
Approved drug PDB Ligand
lirafugratinib is an approved drug
Compound class: Synthetic organic
Comment: Lirafugratinib (RLY-4008) is a tyrosine kinase inhibitor with antineoplastic activity. It is one of the chemical compounds that are claimed in patent WO2020231990A1 as FGFR inhibitors [2]. Shubbiah et al. disclosed RLY-4008 as the first selective FGFR2 inhibitor [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 120.84
Molecular weight 509.2
XLogP 4.75
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Cc1ccnc(n1)Oc1ccc(cc1F)c1c(c2ccc(cc2)NC(=O)C(=C)C)n(c2c1c(N)ncn2)C
Isomeric SMILES Cc1nc(ncc1)Oc1c(cc(cc1)c1c(n(c2ncnc(c12)N)C)c1ccc(cc1)NC(=O)C(=C)C)F
InChI InChI=1S/C28H24FN7O2/c1-15(2)27(37)35-19-8-5-17(6-9-19)24-22(23-25(30)32-14-33-26(23)36(24)4)18-7-10-21(20(29)13-18)38-28-31-12-11-16(3)34-28/h5-14H,1H2,2-4H3,(H,35,37)(H2,30,32,33)
InChI Key XOQVZSSDIQQUGO-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Lirafugratinib (RLY-4008) was progressed to clinical trials to evaluate its potential to treat solid tumours with FGFR2 gene amplification, fusions or mutations. First approval was granted by the US FDA in September 2026, to treat metastatic cholangiocarcinoma with confirmed FGFR2 gene alteration.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04526106 REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors Phase 1/Phase 2 Interventional Relay Therapeutics, Inc.